Ngwaahịa

Linagliptin Intermediate F, nke a makwaara dị ka 3-aminopperidine-1-carboxylic acid, bụ ihe dị mkpa kemịkalụ kemịkalụ na njikọ nke linagliptin, ọgwụ eji agwọ ụdị ọrịa shuga mellitus nke 2.Linagliptin so na klaasị ọgwụ akpọrọ dipeptidyl peptidase-4 (DPP-4) inhibitors, nke na-enyere aka ịhazi ọkwa shuga dị n'ọbara.Ọ na-arụ ọrụ dị ka isi ihe mgbochi ụlọ iji mepụta usoro kemịkalụ pụrụ iche nke linagliptin site n'inwe ọtụtụ mmeghachi omume.A na-eji etiti a eme ihe kpọmkwem na njikọ nke mgbanaka isi piperidine nke usoro ihe omimi nke linagliptin. Ozugbo emechara ya, linagliptin na-eme ihe site na igbochi ọrụ enzymatic nke DPP-4.Ndị na-egbochi DPP-4 na-arụ ọrụ site na igbochi ndakpọ nke homonụ incretin, dị ka glucagon-dị ka peptide-1 (GLP-1), bụ ndị na-ahụ maka ịkpali mwepụta insulin na igbochi nzuzo glucagon.Site na igbochi DPP-4, linagliptin na-agbatị ọrụ nke homonụ incretin ndị a, na-eduga n'ịkwalite njikwa shuga n'ọbara n'ime ndị nwere ụdị ọrịa shuga 2. A na-enyekarị Linagliptin ka ọ bụrụ mgbakwunye nri na mmega ahụ na njikwa ụdị ọrịa shuga 2.A maara ya maka ogologo ndụ ọkara ndụ ya, nke na-enye ohere maka ịdị mma dosing otu ugboro kwa ụbọchị.E gosipụtara Linagliptin iji belata ọkwa hemoglobin A1c nke ọma, akara nke njikwa glucose ogologo oge, yana ndị ọrịa na-anabata ya nke ọma. Ojiji Linagliptin Intermediate F na njikọ nke linagliptin na-egosipụta ọrụ dị mkpa ya na mmepụta ọgwụ. nke nwere ike imetụta ndụ ndị mmadụ nwere ụdị ọrịa shuga 2 nke ukwuu.Site na ntinye aka na imepụta kemịkalụ pụrụ iche nke linagliptin, etiti a na-enyere ngwaahịa ikpeazụ aka igbochi DPP-4 nke ọma ma melite njikwa glycemic. eji maka ọgwụgwọ ụdị ọrịa shuga 2.Ọrụ ya n'imepụta usoro ihe omimi nke linagliptin na-emesi ike mkpa ọ dị na mmepụta ọgwụ nke nwere ike imezi njikwa shuga ọbara ma kwalite njikwa ọrịa shuga.Site na igbochi DPP-4, linagliptin na-enyere aka ịhazi ọkwa glucose ọbara ma na-enye aka na ọdịmma nke ndị nwere ụdị ọrịa shuga 2.